mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

NCT06791512 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

166

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer (CRC)
pMMR/MSS Adenocarcinoma of the Colon or Rectum

Interventions

DRUG: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody
DRUG: mFOLFOX6

Sponsor

Jun Huang